Nitric oxide, a mediator of inflammation, suppresses tumorigenesis

Cancer Research

Volumn 64, Issue 19, 2004, Pages 6849-6853

  Hussain, S Perwez ^a   Trivers, Glennwood E ^a   Hofseth, Lorne J ^b   He, Peijun ^a   Shaikh, Irfan ^a   Mechanic, Leah E ^a   Doja, Saira ^a   Jiang, Weidong ^a   Subleski, Jeffrey ^c   Shorts, Lynnette ^c   Haines, Diana ^d   Laubach, Victor E ^e   Wiltrout, Robert H ^c   Djurickovic, Draginja ^d   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SAIC FREDERICK INC   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CELL CYCLE PROTEIN; FAS ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; KI 67 ANTIGEN; NITRIC OXIDE; PROTEIN P21; PROTEIN P53; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; CROSS BREEDING; DISEASE COURSE; GENE EXPRESSION REGULATION; KNOCKOUT MOUSE; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SARCOMA; SPLEEN; THYMUS;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE MODELS, ANIMAL; FAS LIGAND PROTEIN; FEMALE; INBREEDING; INFLAMMATION MEDIATORS; INTERLEUKIN-10; KI-67 ANTIGEN; LYMPHOMA, T-CELL; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; SARCOMA, EXPERIMENTAL; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 4944225542     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2201     Document Type: Article

References (34)

1. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (Lond.) 1992;356: 215-21.
2. Jacks T, Remington L, Williams B, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994;4:1-7.
3. Harvey M, McArthur MJ, Montgomery CA Jr, Bradley A, Donehower LA. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J 1993;7:938-43.
4. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature (Lond.) 2000; 408:307-10.
5. Forrester K, Ambs S, Lupold SE, et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase (NOS2) expression by wild-type p53. Proc Natl Acad Sci USA 1996;93:2442-7.
6. Ambs S, Ogunfusika MO, Merriam WG, Bennett WP, Billiar TR, Harris CC. Up-regulation of NOS2 expression in cancer-prone p53 knockout mice. Proc Natl Acad Sci USA 1998;95:8823-8.
7. Nathan C. Immunology: oxygen and the inflammatory cell. Nature (Lond.) 2003;422: 675-6.
8. Ignarro LJ. Physiology and pathophysiology of nitric oxide. Kidney Int Suppl 1996;55:S2-5.
9. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003;3:276-85.
10. Laubach VE, Shesely EG, Smithies O, Sherman PA. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci USA 1995;92:10688-92.
11. Kim Y-M, Chung H-T, Simmons RL, Billiar TR. Cellular non-heme iron content is a determinant of nitric oxide-mediated apoptosis, necrosis, and caspase inhibition. J Biol Chem 2000;275:10954-61.
12. Rubbo H, Tarpey M, Freeman BA. Nitric oxide and reactive oxygen species in vascular injury. Biochem Soc Symp 1995;61:33-45.
13. Wu-Hsieh BA, Chen W, Lee HJ. Nitric oxide synthase expression in macrophages of Histoplasma capsulatum-infected mice is associated with splenocyte apoptosis and unresponsiveness. Infect Immun 1998;66:5520-6.
14. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002;2:277-88.
15. Chlichlia K, Peter ME, Rocha M, et al. Caspase activation is required for nitric oxide-mediated, CD95(APO-1/Fas)-dependent and independent apoptosis in human neoplastic lymphoid cells. Blood 1998;91:4311-20.
16. Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002;195:161-9.
17. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999;189:1343-54.
18. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95:7556-61.
19. Bauer PM, Buga GM, Ignarro LJ. Role of p42/p44 mitogen-activated-protein kinase and p21waf1/cip1 in the regulation of vascular smooth muscle cell proliferation by nitric oxide. Proc Natl Acad Sci USA 2001;98:12802-7.
20. Hofseth LJ, Saito S, Hussain SP, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci USA 2003;100:143-8.
21. Niedbala W, Wei XQ, Campbell C, Thomson D, Komai-Koma M, Liew FY. Nitric oxide preferentially induces type 1 T-cell differentiation by selectively up-regulating IL-12 receptor beta 2 expression via cGMP. Proc Natl Acad Sci USA 2002;99: 16186-91.
22. Airoldi I, Di Carlo E, Banelli B, et al. The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Invest 2004;113:1651-9.
23. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11-22.
24. Ohkusu-Tsukada K, Tsukada T, Isobe K. Accelerated development and aging of the immune system in p53-deficient mice. J Immunol 1999;163:1966-72.
25. Gardner CR, Laskin JD, Dambach DM, et al. Reduced hepatotoxicity of acetaminophen in mice lacking inducible nitric oxide synthase: potential role of tumor necrosis factor-alpha and interleukin-10. Toxicol Appl Pharmacol 2002;184:27-36.
26. Seo N, Hayakawa S, Takigawa M, Tokura Y. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 2001;103:449-57.
27. Yang AS, Lattime EC. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses. Cancer Res 2003;63: 2150-7.
28. Matsumoto A, Comatas KE, Liu L, Stamler JS. Screening for nitric oxide-dependent protein-protein interactions. Science (Wash. DC) 2003;301:657-61.
29. Bogdan C, Rollinghoff M, Diefenbach A. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr Opin Immunol 2000;12:64-76.
30. Radi R, Cassina A, Hodara R. Nitric oxide and peroxynitrite interactions with mitochondria. Biol Chem 2002;383:401-9.
31. Liu G, Parant JM, Lang G, et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet 2004; 36:63-8.
32. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003; 63:6643-50.
33. Parant JM, Lozano G. Disrupting TP53 in mouse models of human cancers. Hum Mutat 2003;21:321-6.
34. Tatemichi M, Tazawa H, Masuda M et al. Suppression of thymic lymphomas and increased non-thymic lymphomagenesis in Trp53-deficient mice lacking inducible nitric oxide synthase gene. Int J Cancer 2004;111:819-28.